Suven Pharmaceuticals (BOM:543064) Total Current Assets : ₹11,677 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suven Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Suven Pharmaceuticals's total current assets for the quarter that ended in Sep. 2024 was ₹11,677 Mil.

Suven Pharmaceuticals Total Current Assets Historical Data

The historical data trend for Suven Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Pharmaceuticals Total Current Assets Chart

Suven Pharmaceuticals Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Current Assets

Get a 7-Day Free Trial

3,916.48

5,647.85

11,279.32

10,110.46

12,631.86

Suven Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial															11,690.69	-	12,631.86	-	11,676.50

Suven Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Suven Pharmaceuticals's Total Current Assets for the fiscal year that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	8211.267	+	1403.585	+	2311.956	+	705.055
	=	12,632

Suven Pharmaceuticals's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6729.8	+	1856.5	+	2154.8	+	935.4
	=	11,677

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Suven Pharmaceuticals (BOM:543064) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Suven Pharmaceuticals's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6729.8	-	4771.4	+	0.75 * 1839.5	+	0.5 * 2154.8
=	4,415

Suven Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of Suven Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Suven Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Pharmaceuticals Ltd (BOM:543064) » Definitions » Total Current Assets

Traded in Other Exchanges

SUVENPHAR:India

Address

No. 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, TG, IND, 500081

Website

https://www.suvenpharm.com

Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.

Suven Pharmaceuticals Headlines

No Headlines